John Bottjer

If you're a refractive surgeon, your biggest competitor is not your neighbor down the street. It's indifference and lack of awareness. I receive google news alerts on a variety of topics and this one in Forbes caught me by surprise yesterday morning. How is it possible that 𝟮𝟱 𝘆𝗲𝗮𝗿𝘀 𝗹𝗮𝘁𝗲𝗿, we are still addressing the basic questions about LASIK? This is an unfortunate example of how we as an industry (surgeons, manufacturers and other stakeholders) have done a terrible job of educating the public on the benefits of vision correction procedures. Together, we can do better. Full article: https://lnkd.in/drm32jhm #ophthalpreneurs #privatepractice #leadership #ophthalmology #ophthalmologist #refractivesurgery #lensreplacement #personalizedvision

43

15 Comments

"Exciting news! Check out this insightful post by Hashem Al-Ghaili, where he shares valuable insights into [briefly mention the topic or key points discussed]. It's inspiring to see such informative content that helps us stay informed and engaged. Thanks, Hashem, for sharing your expertise with us! #Science #KnowledgeSharing #Learning"

23

Part 3 of 3. We start with the philosophy that if there were no additional costs and no compromises, all patients would want the broadest range of vision. Then we downgrade until we arrive at their personal best possible option. Parts 1 and 2 in comments. #ophthalmology #privatepractice #leadership #refractivesurgery #lensreplacement #personalizedvision #ophthalpreneurs

55

9 Comments

BiVACOR® Implants First-in-Human Total Artificial Heart at The Texas Heart Institute as a bridge to heart transplant Houston, Texas, July 25, 2024 – The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). BiVACOR’s TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart. The first-in-human clinical study aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended. Following this first implantation completed at Baylor St. Luke’s Medical Center in the Texas Medical Center, four additional patients are to be enrolled in the study. “The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” said Dr. Joseph Rogers, President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research. “We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.” Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR said, “I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S., and is increasing in prevalence. Heart transplantations are reserved for those with severe heart failure and are limited to fewer than 6,000 procedures per year globally. Media Contacts: Inquiries related to the BiVACOR: Alexander Romero-Wilson, Health Commerce [email protected]

157

2 Comments

"In the same way that you, Doc, are an expert in surgery and vision-correcting technologies, your patients are also experts. They are experts in themselves." Below is part 1 of a 3-part series reflecting on Guendalina Graffigna's presentation at Ophthalpreneurs in Stresa. Want to know how we at ADVALIA - CARONES Vision leverage our patients' expertise to personalize their vision, arriving at a 𝟗𝟏% conversion to presbyopia-mitigating lenses? Take a listen below. Part 2 to follow tomorrow. #ophthalmology #leadership #privatepractice #refractivesurgery #lensreplacement #personalizedvision

51

3 Comments